First, CD58 expression patterns, immunorelevance, prognostic significance, and clinical associations were evaluated using transcriptome data from TCGA (33 cancers, n=10,535) and CGGA (glioma, n=1,018). This evidence concerns the gene CD58 and central nervous system cancer.